The stock of Abbott Laboratories ABT + 4.17% grew 1.6% Thursday in premarket trading after the company reported earnings that were below those of a year earlier but above analyst expectations. The company’s net income for the third quarter was $1.375 billion or 78 cents per share. This is down from $2.018 million or $1.14 per share in the previous period. The adjusted earnings per share came in at $1.08, which was higher than the $1.05 FactSet consensus. Sales dropped 11.4%, to $9.978 Billion. However, they were still ahead of the $9.972 Billion FactSet consensus. COVID-19-related sales fell from the previous year. The company still expects a full-year adjusted earnings per share of $4.30 to $4.50. The company expects sales without COVID to increase by low double digits, and COVID-related sales will be around $1.3 billion. The stock is down 2.3% year-to-date, while S&P500 SPX is up 19%.